NASDAQ:ALMS Alumis Q2 2026 Earnings Results & Report $6.12 -0.44 (-6.63%) As of 02:56 PM Eastern This is a fair market value price provided by Massive. Learn more. Alumis missed analyst expectations on both earnings and revenue in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$1.11 versus the -$0.7670 consensus estimate, while revenue of $1.66 million fell short of the $3.65 million estimate by $1.99 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 13, 2026TimeAfter Market ClosesConference Call4:00 PM ET Alumis EPS ResultsActual EPS-$1.11Consensus EPS -$0.7670Beat/MissMissed by -$0.3430One Year Ago EPSN/AEPS Beat Rate0 of last 7 quartersAlumis Revenue ResultsActual Revenue$1.66 millionExpected Revenue$3.65 millionBeat/MissMissed by -$1.99 millionYoY Revenue GrowthN/AUpcoming EarningsAlumis' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Alumis Q2 2026 Earnings FAQ Did Alumis beat earnings estimates for Q2 2026? Alumis (NASDAQ:ALMS) reported earnings of -$1.11 per share for Q2 2026, missing the consensus estimate of -$0.7670. The report was announced on Thursday, August 13, 2026. What was Alumis' revenue for Q2 2026? Alumis reported revenue of $1.66 million for Q2 2026, against a consensus estimate of $3.65 million. When is Alumis' next earnings date? Alumis' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Alumis on the company's earnings history page. Alumis Earnings HeadlinesAlumis Inc. (ALMS) - What Are Investment Firms Saying About This Stock?October 12 at 2:15 AM | americanbankingnews.comAlumis Reports Positive Phase 3 Data With EnvudeucitinibOctober 9, 2026 | rttnews.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.October 14 at 1:00 AM | Porter & Company (Ad)Alumis Says Phase 3 Data From Plaque Psoriasis Program Reiterate Treatment's Potential as 'Leading' Oral TherapyOctober 9, 2026 | finance.yahoo.comAlumis Shares New Phase 3 Psoriasis Data For Envudeucitinib; Stock UpOctober 9, 2026 | rttnews.comAlumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life MeasuresOctober 9, 2026 | globenewswire.comSee More Alumis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alumis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alumis and other key companies, straight to your email. Email Address About AlumisAlumis (NASDAQ:ALMS), Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases. The company’s research centers on selective allosteric inhibitors of tyrosine kinase 2 (TYK2), a protein involved in signaling pathways that regulate inflammation and immune responses. Alumis’ lead product candidate is ESK-001, an oral, highly selective TYK2 inhibitor being evaluated in inflammatory and autoimmune conditions, including plaque psoriasis, psoriatic arthritis and systemic lupus erythematosus. The company is also advancing additional pipeline programs, including A-005, an investigational TYK2 inhibitor designed to reach the central nervous system. Alumis was formerly known as Esker Therapeutics and is headquartered in the United States. Its development programs are intended to support the treatment of patients with immune dysfunction in multiple global markets, subject to clinical and regulatory success.View Alumis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
